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Sociodemographic variation in the use of chemotherapy and
radiotherapy in patients with stage IV lung, oesophageal,
stomach and pancreatic cancer: evidence from population-
based data in England during 2013–2014
Katherine E Henson1, Anna Fry1,2, Georgios Lyratzopoulos1,3, Michael Peake1,4,5, Keith J Roberts6 and Sean McPhail1
BACKGROUND: Sociodemographic inequalities in cancer treatment have been generally described, but there is little evidence
regarding patients with advanced cancer. Understanding variation in the management of these patients may provide insights into
likely mechanisms leading to inequalities in survival.
METHODS:We identified 50,232 patients with stage IV lung, oesophageal, pancreatic and stomach cancer from the English national
cancer registry. A generalised linear model with a Poisson error structure was used to explore variation in radiotherapy and
chemotherapy within 6 months from diagnosis by age, sex, deprivation, ethnicity, cancer site, comorbidity and, additionally,
performance status.
RESULTS: There was substantial variation by cancer site, large gradients by age, and non-trivial associations with comorbidity and
deprivation. After full adjustment, more deprived patients were consistently least likely to be treated with chemotherapy alone or
chemotherapy and radiotherapy combined compared with less deprived patients with equally advanced disease stage (treatment
rate ratio: 0.82 95% CI (0.78, 0.87) for CT, 0.78 95% CI (0.71, 0.85) for CTRT p < 0.0001).
CONCLUSIONS: There was marked variation in the management of patients with stage IV cancer. Routinely collected data could be
used for surveillance across all cancers to help reduce treatment variation and optimise outcomes among patients with advanced cancer.
British Journal of Cancer (2018) 118:1382–1390; https://doi.org/10.1038/s41416-018-0028-7
INTRODUCTION
While much previous evidence documents sociodemographic
variation in cancer treatment,1–7 particularly surgery with curative
intent8–11 and lung cancer,12,13 most studies thus far do not take
into account potential confounding by stage at diagnosis.
Relatively little attention has been paid to the management of
patients with stage IV disease, particularly using population-based
data. While for most such patients treatment will be administered
with non-curative intent, variation in management can translate to
substantial differences in survival. These considerations are
particularly applicable to cancer sites with large proportions of
patients diagnosed with stage IV disease.
In England, routine monitoring of treatment of cancer has
historically not been available, particularly for radiotherapy (RT)
and chemotherapy (CT). This has historically been due to limited
data availability and completeness. National audit reports
routinely published treatment rates for some specific cancer sites
and stages; however limited statistical adjustments for socio-
demographic and clinical factors were included.14–16
Treatment among patients with advanced cancers is influenced
by numerous factors such as performance status (a measure of
general well-being, and the ability of a cancer patient to maintain
their normal daily activities), patient age, presence and severity of
comorbidity, perceived benefits and side-effects of treatment and
patient choice. These are largely understandable clinically as
issues that influence a patient’s likely tolerance to treatment, like
age, though probably to a lesser extent.1,7,17,18 However, recent
studies have discussed the sometimes problematic assumed
relationship between frailty and age, and that more sophisticated
measures of frailty should be employed during treatment
decisions to reduce inequalities and offer optimum treatment.19
England has an increasingly robust system of data collection
among patients with cancer and thus it is now possible to study
variation in treatment whilst adjusting for these important factors.
Motivated by the above considerations, we aimed to describe
the population level uptake and variation of treatment among
patients with stage IV lung, pancreas, stomach and oesophageal
cancer, with a particular hypothesis that sociodemographic factors
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explain some of the variation. Understanding variation in the
management of these patients may provide insights into likely
mechanisms leading to inequalities in survival and help develop
interventions to reduce them. We focused on four cancer sites
with a high proportion of stage IV cancers diagnosed, and where
prior evidence indicates that use of surgery in patients with
metastatic disease is rare (this was supported in our cohort of
stage IV patients, with less than 5% recorded to have received
surgery intended to remove the primary tumour). Thus, CT and RT
are the main treatment modalities for stage IV disease, and intent
was assumed to be almost universally non-curative.
PATIENTS AND METHODS
Study population
Patients diagnosed with lung (ICD-10 C34, divided into small cell
(SCLC) (Supplementary Table 1) and non-small cell (NSCLC), selected
as lung cases not identified as small cell), oesophagus (C15),
pancreas (C25) and stomach (C16) cancer during 2013–2014 were
identified from Public Health England’s national cancer registration
data. All patients were resident in England and aged 15–99 years at
diagnosis. Patients identified through their death certificate only (18
patients) were excluded, as were patients with mis-ordered dates
(13 patients), for example a date of death prior to diagnosis.
Cancer registration data, which in isolation contains some
treatment data, was linked with the Radiotherapy Dataset (RTDS)20
and Systemic Anti-Cancer Therapy (SACT)21 data to ascertain
treatment uptake for each patient from 30 days prior to and
183 days following the date of cancer diagnosis. The datasets
were linked on NHS number; therefore the additional treatment-
specific datasets (RTDS and SACT) were only used for patients who
were diagnosed with one tumour in any 6 month period. The
outcome variables were therefore RT (without CT), CT (without RT)
and CTRT, which may have been delivered independently of each
other. Immunotherapies are captured in SACT, and are thus
included as ‘CT’. Brachytherapy episodes were excluded, as were
SACT records for hormonal therapy and treatment other than
active anti-cancer therapy (such drug therapies for the manage-
ment of bone metastasis such as zoledronic acid, pamidronate
and denosumab).
To calculate the income deprivation quintile, each patient’s
postcode at diagnosis (at the Lower Super Output Area geography)
Table 1. Patient characteristics of stage IV lung, oesophageal, pancreatic and stomach cancers diagnosed in 2013–2014 in England
Number of cancers diagnosed Total
NSCLC % SCLC % Oesophagus % Stomach % Pancreas %
Total 30,431 5,079 4,023 3,588 7,111 50,232
Year of diagnosis
2013 14,979 49 2,532 50 1,847 46 1,783 50 3,288 46 24,429
2014 15,452 51 2,547 50 2,176 54 1,805 50 3,823 54 25,803
Sex
Male 16,839 55 2,712 53 2,898 72 2,401 67 3,715 52 28,565
Female 13,592 45 2,367 47 1,125 28 1,187 33 3,396 48 21,667
Age at cancer diagnosis
<50 847 3 148 3 175 4 262 7 315 4 1,747
50–59 2,953 10 697 14 557 14 366 10 829 12 5,402
60–69 8,135 27 1,761 35 1,218 30 770 21 1,881 26 13,765
70–79 10,075 33 1,771 35 1,234 31 1,180 33 2,275 32 16,535
80+ 8,421 28 702 14 839 21 1,010 28 1,811 25 12,783
Charlson comorbidity index
0 22,840 75 3,922 77 3,285 82 2,816 78 5,461 77 38,324
1 3,661 12 578 11 373 9 395 11 845 12 5,852
2 2,007 7 331 7 192 5 228 6 435 6 3,193
3+ 1,923 6 248 5 173 4 149 4 370 5 2,863
Deprivation quintile
1: least deprived 4,377 14 623 12 731 18 601 17 1,445 20 7,777
2 5,516 18 887 17 832 21 733 20 1,531 22 9,499
3 6,411 21 1,009 20 857 21 741 21 1,577 22 10,595
4 6,862 23 1,192 23 832 21 769 21 1,349 19 11,004
5: most deprived 7,265 24 1,368 27 771 19 744 21 1,209 17 11,357
Ethnicity
White 28,133 92 4,817 95 3,781 94 3,198 89 6,411 90 46,340
Non-white 1,182 4 120 2 91 2 264 7 376 5 2,033
Unknown 1,116 4 142 3 151 4 126 4 324 5 1,859
Performance status
0 2,567 8 414 8 586 15 369 10 418 6 4,354
1+ 14,985 49 3,109 61 1,342 33 1,164 32 1,161 16 21,761
Unknown 12,879 42 1,556 31 2,095 52 2,055 57 5,532 78 24,117
NSCLC non-small cell lung cancer, SCLC small cell lung cancer
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was linked to the income domain of the Index of Multiple
Deprivation 2010.22 Equal population quintiles were derived over
the whole of England from the income domain score, and each
cancer patient was assigned the income deprivation quintile of
their local geography. Ethnicity was self-reported and recorded in
the hospital patient administration systems. If the patient’s
ethnicity was unknown in the cancer registration data, the modal
value from the Hospital Episode Statistics (HES) data23 was used.
Ethnicity is recorded for each hospital episode, and the most
common ethnicity was chosen (or the most recent of these in the
event of a tied number of records). The comorbidity index was
derived as per the Charlson comorbidity index lookup table24 using
in-patient HES data, with the same methodology as described
by Maringe et al (2017),25 but with a different time window: from
27 months to 3 months prior to the cancer diagnosis. Performance
status was obtained from both cancer registration and SACT data,
and is as recorded by the multi-disciplinary team (MDT). The
performance status was measured at both diagnosis and at the
start of each chemotherapy regimen, thus if a patient was assigned
two performance status values, the maximum (most disadvanta-
geous) value was chosen. Vital status was ascertained from the
Office of National Statistics (ONS) mortality data.
Table 2. Treatment rate ratios for chemotherapy alone (CT), radiotherapy alone (RT) and chemotherapy & radiotherapy (CTRT) within 6 months of
diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013–2014 from three unadjusted and three fully adjusted multivariable models
with cancer site, sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index
RT CT CTRT
%a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI)
Unadjusted Fully adjusted Unadjusted Fully adjusted Unadjusted Fully adjusted
Sex
Male 13 Ref Ref 24 Ref Ref 11 Ref Ref
Female 12 0.88 (0.84, 0.92) 0.85 (0.81, 0.89) 23 0.90 (0.86, 0.93) 0.97 (0.93, 1.00) 12 1.02 (0.97, 1.08) 0.95 (0.91, 1.01)
p for heterogeneityb <0.0001 <0.0001 <0.0001 0.08 0.36 0.08
Age at cancer diagnosis
<50 9 0.57 (0.48, 0.67) 0.65 (0.55, 0.77) 45 1.35 (1.25, 1.46) 1.24 (1.15, 1.34) 21 1.11 (0.99, 1.24) 1.41 (1.26, 1.58)
50–59 12 0.86 (0.79, 0.94) 0.91 (0.83, 0.99) 34 1.04 (0.99, 1.10) 1.01 (0.95, 1.06) 22 1.27 (1.18, 1.36) 1.33 (1.24, 1.43)
60–69 13 Ref Ref 32 Ref Ref 17 Ref Ref
70–79 14 1.21 (1.14, 1.29) 1.20 (1.13, 1.28) 24 0.78 (0.75, 0.82) 0.79 (0.76, 0.83) 9 0.55 (0.51, 0.58) 0.56 (0.53, 0.60)
80+ 12 1.22 (1.14, 1.30) 1.13 (1.05, 1.21) 7 0.21 (0.20, 0.23) 0.22 (0.21, 0.24) 2 0.14 (0.12, 0.15) 0.15 (0.13, 0.17)
p for heterogeneityb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Charlson comorbidity index
0 13 Ref Ref 26 Ref Ref 13 Ref Ref
1 12 1.01 (0.93, 1.09) 0.95 (0.88, 1.03) 19 0.76 (0.71, 0.81) 0.86 (0.81, 0.91) 9 0.70 (0.63, 0.76) 0.81 (0.74, 0.89)
2 12 1.08 (0.98, 1.20) 0.99 (0.89, 1.09) 16 0.63 (0.58, 0.69) 0.74 (0.68, 0.81) 8 0.64 (0.56, 0.73) 0.78 (0.69, 0.89)
3+ 12 1.15 (1.03, 1.28) 0.98 (0.88, 1.10) 11 0.43 (0.39, 0.48) 0.57 (0.51, 0.64) 4 0.32 (0.26, 0.38) 0.41 (0.34, 0.50)
p for heterogeneityb 0.04 0.67 <0.0001 <0.0001 <0.0001 <0.0001
Deprivation quintile
1: least deprived 12 Ref Ref 27 Ref Ref 12 Ref Ref
2 12 1.04 (0.96, 1.13) 1.02 (0.94, 1.11) 25 0.95 (0.90, 1.01) 0.95 (0.90, 1.01) 12 1.04 (0.95, 1.14) 0.96 (0.88, 1.04)
3 13 1.12 (1.03, 1.22) 1.09 (1.00, 1.18) 23 0.88 (0.83, 0.93) 0.89 (0.84, 0.94) 11 1.01 (0.93, 1.10) 0.90 (0.82, 0.98)
4 13 1.09 (1.00, 1.18) 1.04 (0.96, 1.13) 23 0.86 (0.81, 0.92) 0.86 (0.81, 0.91) 11 1.04 (0.96, 1.14) 0.84 (0.77, 0.91)
5: most deprived 13 1.14 (1.05, 1.23) 1.08 (1.00, 1.18) 22 0.85 (0.80, 0.90) 0.82 (0.78, 0.87) 11 1.07 (0.98, 1.17) 0.78 (0.71, 0.85)
p for heterogeneityb 0.01 0.18 <0.0001 <0.0001 0.48 <0.0001
Ethnicity
White 13 Ref Ref 24 Ref Ref 11 Ref Ref
Non-white 12 0.85 (0.75, 0.96) 0.91 (0.80, 1.04) 29 1.13 (1.04, 1.22) 1.01 (0.92, 1.10) 14 1.07 (0.95, 1.21) 1.07 (0.95, 1.21)
Unknown 11 0.93 (0.81, 1.08) 0.93 (0.81, 1.07) 17 0.80 (0.71, 0.89) 0.75 (0.67, 0.84) 7 0.67 (0.56, 0.79) 0.67 (0.56, 0.79)
p for heterogeneityb 0.03 0.24 <0.0001 <0.0001 <0.0001 <0.0001
Cancer site
NSCLC 18 Ref Ref 18 Ref Ref 12 Ref Ref
SCLC 5 0.25 (0.22, 0.29) 0.26 (0.23, 0.29) 33 1.89 (1.79, 1.99) 1.61 (1.52, 1.70) 32 3.31 (3.12, 3.51) 2.91 (2.74, 3.09)
Oesophagus 10 0.47 (0.43, 0.52) 0.47 (0.42, 0.52) 37 2.04 (1.92, 2.16) 1.88 (1.77, 1.99) 8 0.57 (0.51, 0.64) 0.47 (0.42, 0.53)
Stomach 5 0.25 (0.21, 0.29) 0.25 (0.21, 0.29) 36 2.14 (2.02, 2.28) 2.16 (2.03, 2.30) 4 0.26 (0.21, 0.31) 0.23 (0.19, 0.27)
Pancreas 1 0.08 (0.07, 0.10) 0.09 (0.07, 0.10) 27 1.86 (1.76, 1.96) 1.78 (1.68, 1.87) 1 0.12 (0.10, 0.15) 0.10 (0.09, 0.13)
p for heterogeneityb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CI confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, TRR treatment rate ratio. a Proportion of patients recorded to receive
treatment in each category. b Performed jointly across all categories of each variable, using a post-estimation Wald test
Variation of stage IV treatment in England
K. E. Henson et al.
1384
Statistical analysis
Each individual entered the analysis at 31 days before the date of
cancer diagnosis (to allow for treatment commencing prior to
diagnosis date, as defined under the European Network of Cancer
Registries (ENCR) rules which prioritise date of pathology26) and
was censored at the earliest of date of first treatment, death (from
the patient’s vital status), or end of the 6 months post-diagnosis
follow up. 1.0% of RT events and 0.2% of CT events occurred in the
31 day period prior to ENCR cancer diagnosis date.
To account for varied survival times among the cohort, a model
was chosen to account for time at risk, as defined above. Hazard
rate ratios (for treatment vs. no treatment, henceforth called
treatment rate ratios (TRR)) were calculated using a generalised
linear model with a Poisson error structure on collapsed data27
where the treatment rate in the reference population was taken as
zero. This was performed using the STRS program in Stata 13.1.27,28
This modelling approach for excess mortality is the analogue of the
relative survival approach. Individual patient-level data was used;
therefore exact survival times were available. The data was
collapsed for ease of computation, as Dickman and colleagues
demonstrated equivalent results to un-collapsed data.27 The excess
hazards are assumed to be constant throughout each month of
follow-up therefore a Poisson process is assumed for the rate of first
treatments per follow-up interval.27 The hazard is dependent on a
subset of the explanatory variables (age, sex and follow-up period).
Where patients received both RT and CT, the start date of this
combined treatment was considered to be the first event.
Separate regression models were performed for: RT (without
CT), CT (without RT) and CTRT. The factors investigated were:
cancer site, sex, age (<50, 50–59, 60–69, 70–79, 80+), socio-
demographic deprivation (income deprivation quintile: 1—least
deprived, 2, 3, 4, 5—most deprived), ethnicity (white, non-white,
unknown) and Charlson comorbidity index (0, 1, 2, 3+).29
Supplementary analyses included performance status as an
explanatory variable in the multivariable regression model
(missing data precluded its use as a main explanatory variable).
Due to theoretical concerns of associations of treatment modality
with morphology subtypes, we also conducted additional analysis
of dominant subtypes restricting the tumour cohort to oesopha-
geal, pancreatic and stomach adenocarcinomas (ICD-O-2 morphol-
ogies 8140-8576).
Tests for heterogeneity were performed jointly across all
categories of each variable, using a post-estimation Wald test.




50,232 patients with stage IV lung, oesophageal, stomach and
pancreatic cancers were diagnosed during 2013–2014, and cohort
characteristics for each of the cancer sites are summarised in
Table 1. Across all sites, 24% received CT (without RT), 13% of
patients received RT (without CT) and 11% received both CT and
RT (CTRT), which varied by cancer type from 1% for CTRT and RT
among patients with pancreatic cancer to 37% for CT among
patients with oesophageal cancer (Table 2). The proportion of
patients who died during the 6 month follow-up period varied
from 57% to 78% for oesophageal and pancreatic cancer,
respectively, and among these patients the median survival time
varied from 41 days (pancreatic and SCLC) to 63 days (oesopha-
geal) (Supplementary Table 2).
Overall variation in treatment usage
Treatment rates varied significantly across cancer sites (p <
0.0001). RT was used more frequently in patients with NSCLC,
CT in patients with stomach cancer and CTRT in patients with
SCLC (Table 2). Full adjustment attenuated crude TRR values up to
33% (Table 2), therefore, only adjusted results are presented in
Table 3 onwards. Across all cancer sites, there was a significant
association between female sex and lower rate of RT (p < 0.0001),
but there was no evidence for association by sex for CT or CTRT
use (p= 0.08 for both). The sex gradient in RT use among NSCLC
was driven by non-squamous tumours (Supplementary Table 3).
There was no difference in treatment use by known ethnicity.
Analyses of radiotherapy and chemotherapy independently of the
other treatment found no substantive differences, except for an
association between increasing age at diagnosis and decreasing
use of radiotherapy (Supplementary Table 4). Restriction to upper
gastrointestinal adenocarcinomas (Supplementary Table 5)
demonstrated highly concordant patterns of variation with that
observed for results of all morphologies combined for upper
gastrointestinal cancers (Table 2), with an expected loss of
significance due to diminished sample size among stratified
results (data not shown).
Variation by age at cancer diagnosis
For all cancer sites (except pancreas, p= 0.78) there was a positive
association between older age and higher RT rate (p < 0.0001;
Table 3). The steepest association was for SCLC (TRR: 0.35 (95% CI
0.09, 1.43) for ages <50 to 3.58 (95% CI 2.54, 5.05) for ages 80+).
There was very strong statistical evidence for associations
between increasing age and lower CTRT use for all sites (p <
0.0001; Table 4), this association being steeper for pancreatic
cancer, with TRRs ranging from 1.77 (95% CI 0.86, 3.63) for ages
<50 to 0.28 (95% CI 0.12, 0.68) for ages 80+. Older age was
associated with a lower rate of CT (p < 0.0001; Table 5), except for
SCLC, with the highest use in patients aged 70–79 (TRR: 1.26 (95%
CI 1.13, 1.41)).
Variation by deprivation
Mostly, increasing deprivation quintile was associated with
decreasing use of CT and CTRT (Tables 4 and 5). The steepest
association was oesophageal cancer, as the TRR among patients in
the most deprived quintile was 0.77 (95% CI 0.65, 0.91) for CT and
0.61 (95% CI 0.43, 0.87) for CTRT. Exceptions with no association
were SCLC for CT, and stomach and pancreas for CTRT. There was
no evidence of an association of deprivation with RT (p= 0.18;
Table 2).
Variation by Charlson comorbidity index
Increasing comorbidity index was associated with decreasing CT
and CTRT rates (p < 0.0001; Table 2). The steepest association was for
NSCLC and CTRT (the TRR among patients with a comorbidity index
of 3+ was 0.35 (95% CI 0.27, 0.45)) (Table 4). The exceptions with no
significant association were SCLC and CT (Table 5), and oesophagus,
stomach and pancreas and CTRT (Table 4). For most sites, no
association was found between comorbidity and RT, except for a
positive association with SCLC (p= 0.02) of 1.80 (95% CI 1.17, 2.77)
among patients with a comorbidity index of 3+ (Table 3).
Association with performance status
Performance status (PS) was known for 52% of the cohort.
Inclusion of PS made no substantive difference to the overall
associations (Supplementary Table 6). However, there was a
significant association with PS for all treatments (p < 0.0001). In
stratified analysis (by broader PS groups), for example, no
association was found between CTRT and comorbidity nor
deprivation among patients with a PS of 0 (p= 0.62 and
p= 0.47, respectively; Supplementary Table 7).
DISCUSSION
Our population-based study of patients with stage IV lung,
oesophageal, stomach and pancreatic cancer aimed to define
uptake and variation in treatment use. The main finding was
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significant variation in the rates of CT and RT, for patients who
receive one treatment alone or both within 6 months post
diagnosis. As expected on clinical grounds, there was significant
heterogeneity by cancer type, given the variable efficacy of
different treatment modalities in different cancers. After account-
ing for this, variation was largely driven by age at cancer diagnosis,
but non-trivial associations with comorbidity and deprivation were
also observed, and additionally associations of sex with RT use.
More variation in treatment appeared to align to where clinical
guidelines are less clear. One example of this was the differential
(by sex) use of RT among patients with non-squamous NSCLC
tumours, where the indication for use of RT is less clear.
Stratification by performance status demonstrated non-trivial
adjustments to these associations suggesting that improved
completeness of performance status may further explain variation
in treatment, particularly as patients with unknown performance
status appeared to have poor health status.
Over half of patients received neither CT nor RT within 6 months
following diagnosis, although a significant fraction died quickly
after diagnosis. Our study focused on RT and/or CT use, though
these patients may have received other treatments, appropriately
not been offered treatment on clinical grounds, received
treatment in a private setting or chosen not to be treated. A
small proportion of patients (estimates vary, but a recent study in
London found 0.6% of breast cancer patients had been treated
privately and did not appear in the cancer registration data30) are
believed to be treated in the private setting, and as they are
treated using standard clinical guidelines the incompleteness of
this data is unlikely to impact the findings of this study. It is also
possible that a limitation in data completeness has contributed to
missing a fraction of the treatments.
Variation in treatment rate by age at diagnosis and Charlson
comorbidity index
We found large gradients in treatment use among patients with
stage IV cancer for both CT and RT with increasing age, and non-
trivial associations with increasing level of comorbidity. Such
variations may be expected, as clinicians and patients must
balance the benefit of palliative therapy against the toxicity of
treatment.17 CT can be highly toxic in patients with multiple
Table 3. Treatment rate ratios for radiotherapy alone (RT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in
2013–2014, from a fully adjusted multivariable model with sex, age at diagnosis deprivation, ethnicity and Charlson comorbidity index, stratified by
cancer site
NSCLC SCLC Oesophagus Stomach Pancreas
%a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI)
Sex
Male 19 Ref 6 Ref 9 Ref 5 Ref 1 Ref
Female 16 0.82 (0.77, 0.86) 5 0.85 (0.67, 1.09) 14 1.41 (1.15, 1.74) 5 0.87 (0.63, 1.19) 1 1.03 (0.69, 1.52)
p for heterogeneityb <0.0001 0.19 0.001 0.39 0.89
Age at cancer diagnosis
<50 15 0.69 (0.57, 0.83) 1 0.35 (0.09, 1.43) 7 0.63 (0.34, 1.18) 1 0.31 (0.09, 1.03) 1 0.65 (0.23, 1.86)
50–59 19 0.93 (0.84, 1.03) 4 1.14 (0.73, 1.77) 6 0.64 (0.43, 0.94) 4 0.99 (0.51, 1.92) 1 0.76 (0.38, 1.51)
60–69 19 Ref 4 Ref 9 Ref 4 Ref 2 Ref
70–79 19 1.13 (1.06, 1.21) 6 1.76 (1.28, 2.40) 12 1.34 (1.04, 1.72) 6 1.80 (1.15, 2.80) 2 1.03 (0.63, 1.66)
80+ 15 0.96 (0.89, 1.04) 10 3.58 (2.54, 5.05) 14 1.86 (1.42, 2.44) 7 2.56 (1.64, 4.00) 1 0.82 (0.46, 1.45)
p for heterogeneityb <0.0001 <0.0001 <0.0001 <0.0001 0.78
Charlson comorbidity index
0 18 Ref 5 Ref 10 Ref 5 Ref 1 Ref
1 16 0.93 (0.85, 1.01) 5 0.95 (0.64, 1.42) 9 0.89 (0.63, 1.26) 7 1.48 (0.99, 2.22) 2 1.64 (0.97, 2.76)
2 16 0.94 (0.84, 1.05) 7 1.43 (0.93, 2.19) 13 1.14 (0.74, 1.74) 7 1.32 (0.77, 2.26) 1 0.79 (0.29, 2.16)
3+ 15 0.92 (0.82, 1.04) 10 1.80 (1.17, 2.77) 10 0.97 (0.60, 1.56) 7 1.27 (0.66, 2.42) 2 1.55 (0.67, 3.59)
p for heterogeneityb 0.19 0.02 0.83 0.23 0.20
Deprivation quintile
1: least deprived 18 Ref 5 Ref 11 Ref 5 Ref 2 Ref
2 18 1.01 (0.92, 1.11) 7 1.30 (0.85, 1.99) 11 1.07 (0.79, 1.45) 6 1.11 (0.71, 1.74) 1 0.72 (0.40, 1.28)
3 18 1.10 (1.01, 1.21) 5 1.02 (0.66, 1.57) 11 1.03 (0.76, 1.39) 6 1.01 (0.63, 1.60) 2 0.87 (0.51, 1.51)
4 17 1.05 (0.96, 1.15) 5 1.15 (0.75, 1.74) 10 0.96 (0.71, 1.32) 5 0.92 (0.58, 1.48) 1 0.65 (0.34, 1.22)
5: most deprived 18 1.11 (1.02, 1.21) 4 0.97 (0.63, 1.47) 9 0.87 (0.63, 1.21) 4 0.66 (0.39, 1.11) 1 0.67 (0.35, 1.29)
p for heterogeneityb 0.05 0.49 0.77 0.31 0.58
Ethnicity
White 18 Ref 5 Ref 10 Ref 5 Ref 1 Ref
Non-white 18 0.86 (0.75, 1.00) 8 1.32 (0.68, 2.59) 12 1.24 (0.68, 2.28) 6 1.68 (0.99, 2.86) 2 1.19 (0.51, 2.78)
Unknown 15 0.89 (0.76, 1.04) 8 1.82 (0.99, 3.35) 5 0.52 (0.26, 1.05) 5 1.22 (0.54, 2.77) 2 1.66 (0.72, 3.82)
p for heterogeneityb 0.05 0.12 0.14 0.15 0.46
CI confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, TRR treatment rate ratio. a Proportion of patients recorded to receive
treatment in each category. b Performed jointly across all categories of each variable, using a post-estimation Wald test
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comorbidities, which is supported by our findings of reduced
usage among those with more comorbidity. Palliative RT for
advanced disease typically has a very low rate of side effects
therefore would be expected to be very much less influenced by
the presence of comorbidities. Our findings support this and are
largely consistent with a study of non-surgically treated lung
cancer patients.1 Despite clinical appropriateness in certain
circumstances, under-treatment of elderly patients has been
well-documented for a number of years;18 which may partly
explain why in international comparisons of death rates the
number of excess deaths in England are highest among older
patients with cancer.31–35 Treatment rates of advanced disease do
appear to be higher in the US for some cancer sites, although
evidence is limited.36 In the United Kingdom, however, there has
been shown to be an increasing use of chemotherapy for
advanced NSCLC patients with low performance status;15 there-
fore, the discrepancy with the US study may be reducing.
However, more treatment is not universally preferred, and there
are circumstances where treatment may be more harmful, due to
the health status of the patient and the potential impact of the
side effects of treatment. Understanding the impact of variation
on survival should provide further evidence for this.
The different treatment rates among older, compared to
younger, patients were not explained by the presence of
comorbidity, poor performance status or other demographic
factors. Our study demonstrated positive associations between
the likelihood of RT use and increasing age at diagnosis, and a
negative association with the likelihood of CT and CTRT use. The
association between increasing age at diagnosis and lower CT use
concords with prior US literature.7,37 The association between
increasing age and increasing RT, however, was in contrast to a
recent Danish study,1 which is likely due to differences in stage
distribution of the selected populations. In adjusted analysis,
increasing RT use with increasing age was only observed among
patients not treated by CT. This presumably reflects that RT is
better tolerated among some elderly patients than CT.
Variation in treatment rate by deprivation
A significant association with deprivation was demonstrated for
patients treated with CT alone, and for patients treated with both
Table 4. Treatment rate ratios for chemotherapy & radiotherapy (CTRT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach
cancers in 2013–2014, from a fully adjusted multivariable model with sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index,
stratified by cancer site
NSCLC SCLC Oesophagus Stomach Pancreas
%a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI)
Sex
Male 12 Ref 31 Ref 9 Ref 4 Ref 1 Ref
Female 12 0.96 (0.90, 1.03) 33 1.00 (0.90, 1.10) 6 0.82 (0.63, 1.07) 3 0.63 (0.42, 0.95) 1 1.06 (0.71, 1.57)
p for heterogeneityb 0.22 0.93 0.15 0.03 0.79
Age at cancer diagnosis
<50 29 1.52 (1.33, 1.74) 50 1.31 (1.03, 1.66) 10 0.87 (0.52, 1.44) 9 1.69 (1.00, 2.85) 3 1.77 (0.86, 3.63)
50 – 59 25 1.36 (1.25, 1.49) 47 1.26 (1.10, 1.43) 14 1.37 (1.03, 1.82) 5 1.04 (0.60, 1.78) 3 2.07 (1.24, 3.48)
60 – 69 18 Ref 39 Ref 10 Ref 5 Ref 2 Ref
70 – 79 9 0.53 (0.49, 0.58) 25 0.59 (0.53, 0.67) 7 0.75 (0.57, 0.98) 3 0.56 (0.35, 0.88) 1 0.77 (0.45, 1.32)
80+ 2 0.11 (0.10, 0.13) 11 0.28 (0.22, 0.35) 2 0.24 (0.14, 0.40) 1 0.26 (0.13, 0.51) 0 0.28 (0.12, 0.68)
p for heterogeneityb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Charlson comorbidity index
0 13 Ref 34 Ref 9 Ref 4 Ref 2 Ref
1 8 0.73 (0.65, 0.83) 28 0.88 (0.75, 1.04) 9 1.27 (0.88, 1.83) 3 0.93 (0.50, 1.74) 2 1.19 (0.66, 2.14)
2 7 0.71 (0.60, 0.84) 27 0.92 (0.74, 1.14) 5 0.76 (0.41, 1.44) 3 1.06 (0.49, 2.30) 1 0.66 (0.21, 2.11)
3+ 3 0.35 (0.27, 0.45) 15 0.50 (0.36, 0.70) 4 0.71 (0.33, 1.51) 2 0.80 (0.25, 2.55) 0 0.27 (0.04, 1.92)
p for heterogeneityb <0.0001 0.0004 0.33 0.98 0.45
Deprivation quintile
1: least deprived 13 Ref 32 Ref 11 Ref 4 Ref 2 Ref
2 13 0.98 (0.88, 1.10) 32 0.91 (0.76, 1.09) 9 0.86 (0.63, 1.19) 3 0.93 (0.52, 1.66) 2 1.00 (0.56, 1.77)
3 11 0.86 (0.77, 0.96) 35 1.03 (0.87, 1.23) 7 0.70 (0.50, 0.98) 4 1.16 (0.67, 2.01) 1 0.71 (0.38, 1.33)
4 11 0.82 (0.74, 0.92) 31 0.87 (0.73, 1.03) 8 0.71 (0.51, 0.99) 4 0.96 (0.55, 1.69) 1 1.00 (0.55, 1.82)
5: most deprived 11 0.77 (0.69, 0.85) 30 0.81 (0.68, 0.96) 7 0.61 (0.43, 0.87) 3 0.90 (0.50, 1.62) 1 0.84 (0.44, 1.63)
p for heterogeneityb <0.0001 0.009 0.04 0.91 0.79
Ethnicity
White 12 Ref 32 Ref 8 Ref 4 Ref 1 Ref
Non-white 18 1.16 (1.01, 1.33) 31 0.83 (0.59, 1.15) 10 1.24 (0.64, 2.43) 5 1.08 (0.59, 1.97) 1 0.39 (0.12, 1.26)
Unknown 8 0.67 (0.55, 0.83) 21 0.73 (0.51, 1.05) 3 0.39 (0.16, 0.95) 2 0.53 (0.13, 2.16) 1 0.46 (0.11, 1.88)
p for heterogeneityb 0.0001 0.13 0.09 0.65 0.17
CI confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, TRR treatment rate ratio. a Proportion of patients recorded to receive
treatment in each category. b Performed jointly across all categories of each variable, using a post-estimation Wald test
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CT and RT within 6 months but no association was found for RT.
This was largely driven by patients with lung or oesophageal
cancers. However, the association with CT alone was not apparent
for SCLC patients, though we were unable to identify a clinical
explanation for this. The deprivation deficit has been documented
in previous studies of oesophagogastric cancer38 and lung
cancer.13,39,40 Our work found the greatest association for CT.
This confirms findings from a systematic review and meta-analysis
of lung cancer treatment, which found a significant negative
association between socioeconomic position and chemotherapy
receipt, but no association with radiotherapy receipt.41 However,
other published studies in England, which have accounted for
travel time, have documented a more pronounced deprivation
deficit in RT compared to CT treatment.42,43 This was largely
attributed to travel times to RT centres. These local delivery issues
may have reduced impact within a national study such as ours,
and differences in the number of hospital attendances for
palliative radiotherapy and chemotherapy delivery as compared
to curative delivery may explain this discrepancy.
Strengths and limitations
This study has population-based coverage, possible because of
access to a wide range of routinely collected health care data in
England. The availability of linked treatment datasets improved
treatment ascertainment for multiple cancer types. There is now a
high level of staging completeness which has allowed the reliable
identification of a group of late stage cancer patients at a national
level.44
Many patients with very advanced, stage IV cancers die very
quickly following diagnosis and one strength of our methodology
is that these patients, who would be very highly unlikely to receive
treatment, have been censored. This allowed the estimates to be
calculated using a patient’s time available for treatment therefore
producing accurate estimates of the treatment rates and
associations.
The main limitation of this study is that patient choice could not
be accounted for. Inclusion of this information may attenuate or
even help explain the associations with deprivation and age.
Patient choice is influenced by many factors,45 and there is limited
Table 5. Treatment rate ratios for chemotherapy alone (CT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in
2013–2014, from a fully adjusted multivariable model with sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index, stratified by
cancer site
NSCLC SCLC Oesophagus Stomach Pancreas
%a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI) %a TRR (95% CI)
Sex
Male 18 Ref 33 Ref 40 Ref 36 Ref 28 Ref
Female 19 1.02 (0.97, 1.08) 33 0.98 (0.89, 1.08) 29 0.84 (0.74, 0.95) 34 0.98 (0.87, 1.11) 25 0.97 (0.88, 1.06)
p for heterogeneityb 0.39 0.74 0.007 0.78 0.48
Age at cancer diagnosis
<50 33 1.18 (1.04, 1.34) 36 0.96 (0.72, 1.26) 61 1.32 (1.08, 1.63) 61 1.17 (0.97, 1.41) 56 1.51 (1.28, 1.78)
50–59 28 1.03 (0.95, 1.12) 30 0.79 (0.67, 0.92) 52 1.07 (0.93, 1.24) 54 1.06 (0.89, 1.26) 42 1.10 (0.97, 1.25)
60–69 26 Ref 35 Ref 48 Ref 53 Ref 38 Ref
70–79 19 0.78 (0.73, 0.83) 38 1.26 (1.13, 1.41) 35 0.73 (0.64, 0.82) 36 0.62 (0.54, 0.71) 25 0.68 (0.61, 0.76)
80+ 5 0.21 (0.19, 0.23) 22 0.82 (0.69, 0.98) 8 0.16 (0.12, 0.20) 10 0.16 (0.13, 0.20) 5 0.15 (0.12, 0.19)
p for heterogeneityb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Charlson comorbidity index
0 20 Ref 34 Ref 40 Ref 38 Ref 29 Ref
1 14 0.84 (0.77, 0.92) 33 0.97 (0.83, 1.13) 27 0.76 (0.62, 0.93) 31 0.92 (0.76, 1.12) 23 0.85 (0.73, 0.98)
2 12 0.72 (0.63, 0.82) 29 0.84 (0.69, 1.04) 22 0.64 (0.47, 0.86) 26 0.75 (0.57, 0.98) 18 0.76 (0.60, 0.96)
3+ 7 0.49 (0.41, 0.58) 32 1.06 (0.84, 1.33) 14 0.43 (0.28, 0.64) 15 0.53 (0.35, 0.80) 12 0.54 (0.40, 0.73)
p for heterogeneityb <0.0001 0.39 <0.0001 0.004 <0.0001
Deprivation quintile
1: least deprived 21 Ref 32 Ref 40 Ref 38 Ref 30 Ref
2 19 0.92 (0.84, 1.01) 33 1.05 (0.87, 1.25) 35 0.85 (0.72, 1.00) 38 1.04 (0.88, 1.24) 29 0.99 (0.87, 1.13)
3 17 0.85 (0.77, 0.92) 32 0.97 (0.82, 1.16) 37 0.92 (0.79, 1.08) 36 0.98 (0.82, 1.18) 27 0.92 (0.80, 1.05)
4 17 0.81 (0.75, 0.89) 34 1.10 (0.92, 1.30) 37 0.90 (0.76, 1.05) 34 0.87 (0.72, 1.03) 24 0.82 (0.71, 0.95)
5: most deprived 17 0.77 (0.71, 0.84) 35 1.16 (0.98, 1.37) 34 0.77 (0.65, 0.91) 32 0.81 (0.68, 0.98) 24 0.78 (0.67, 0.91)
p for heterogeneityb <0.0001 0.13 0.03 0.02 0.002
Ethnicity
White 18 Ref 34 Ref 37 Ref 36 Ref 27 Ref
Non-white 25 1.10 (0.97, 1.24) 32 0.90 (0.65, 1.25) 41 1.17 (0.84, 1.63) 38 0.80 (0.65, 0.99) 31 0.96 (0.79, 1.17)
Unknown 14 0.79 (0.67, 0.92) 25 0.83 (0.59, 1.16) 36 1.04 (0.79, 1.36) 21 0.59 (0.40, 0.87) 13 0.48 (0.35, 0.65)
p for heterogeneityb 0.003 0.45 0.62 0.004 <0.0001
CI confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, TRR treatment rate ratio. a Proportion of patients recorded to receive
treatment in each category b Performed jointly across all categories of each variable, using a post-estimation Wald test
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population-based data reporting patient choice. More deprived
patients may be less inclined to accept the associated risks of
treatment, the patient–clinician interaction may be impacted and
understanding of the disease may differ,46–48 and there may be
increased fatalism. Having adjusted for co-morbidities and, to a
lesser extent, performance status, it seems unlikely that underlying
ill-health is the only factor explaining the lower treatment rates in
more socially deprived patients. Specifically, the differential
impact of deprivation on the choice of active treatment was less
apparent among those patients with a better performance status.
However, we were not able to fully take account of frailty,19
smoking status or lung function, factors which are particularly
relevant for lung cancer, though less so in the palliative setting. As
always in population-based studies, there are also some limita-
tions relating to data completeness, in particular incomplete data
on performance status and the fact that our index of comorbidity
is based only on in-patient hospital records. More complete
performance status may have explained some of the remaining
variation, particularly among the gastrointestinal cancers where
completeness was the lowest. It is also worth noting that for
oesophageal, pancreatic and stomach cancer, the staging data
completeness increased markedly from 2013 to 2014, thus
increasing the number of stage IV diagnoses in 2014 (Supple-
mentary Table 8).
Further research
This study has clearly demonstrated that unexplained variation in
receipt of treatment exists among a cohort of stage IV cancer
patients in England. However, it is not clear if this variation results
in differences in expected survival for these patients. Statistical
analyses may permit understanding of the excess mortality among
these patients, and the attribution of any excess mortality to
known patient and tumour characteristics, as in a study of short-
term breast cancer mortality.49 This is vital further research among
these patients diagnosed with stage IV disease. This information
also requires further work to define why some patients, particularly
the elderly, are not treated with either radiotherapy or chemother-
apy, as barriers to patients receiving palliative treatment can often
be overcome.50 This is an active area of research among patients
with various cancer types in older patients.51,52
Implications for policy and practice
The main finding is that older patients are, in general, receiving
lower rates of active treatment for their cancers and that these low
rates cannot be fully explained by co-morbidity. It is well known
that there are higher excess death rates from a number of cancers
in older patients in England than in some other countries. The
explanation for this warrants further work and may well be largely
related to patient choice influenced by cultural factors. Healthcare
providers need to examine how they support older patients when
making treatment decisions and policy makers need to improve
the access of cancer teams to such tools as the Comprehensive
Geriatric Assessment.50–52 Qualitative studies and ethnography are
needed to understand the patient-clinician interaction, and its
impact on patient choice of treatment. Data linkages to primary
care information should be explored, to capture unmeasured
morbidity which may explain the variation in treatment received
among these patients.
CONCLUSION
Contributing to a body of evidence documenting age and
deprivation deficits in treatment for cancer patients, our study
defines these deficits as being very evident among patients with
advanced disease requiring essentially palliative treatments.
Factors other than health status appear to be important in
explaining this, as they remain after adjustment for recorded
factors. Clinicians and service planners should consider these
findings and future health policies should attempt to address
them. Strategies should be developed to improve valid routine
collection, processing and analysis of information on patient
choice, to attempt to further understand this complex topic.
Finally, our approach using routinely collected health data can
potentially be used for routine surveillance across all cancer types,
particularly for those cancers not currently covered by National
Audit initiatives, thus to monitor trends in variation over time and
improve outcomes for patients.
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